What is the optimal sequence of systemic therapy for a patient with HR+, gBRCA mutated metastatic breast cancer?
Answer from: Medical Oncologist at Academic Institution
The optimal sequencing of HR positive and BRCA germline positive patients has not been established yet in prospective trials. Studies evaluating PARP inhibitors (either single agent or in combination with chemotherapy) versus chemotherapy included patients with HR positive disease, many of whom rece...
Comments
Medical Oncologist at Joliet Oncology Hematology Associates When do you start parp inhibitors on these patient...
Medical Oncologist at Northwest Medical Specialties PLLC Clinical practice seems to be CDK 4/6 inhibitor pl...
Medical Oncologist at Rocky Mountain Cancer Centers I agree with current trends being CDK 4/6 inhibito...
Medical Oncologist at NYU Winthrop Hospital CD inhibitors:- First line.
PARP Inhibitors:- Sec...
When do you start parp inhibitors on these patient...
Clinical practice seems to be CDK 4/6 inhibitor pl...
I agree with current trends being CDK 4/6 inhibito...
CD inhibitors:- First line. PARP Inhibitors:- Sec...